RxDoctor Payments Data

Cullen Ryburn, MD

Ophthalmology · Loveland, CONPI 1679950976

Payments from drug & device makers

$3,193in general payments, 2019–2025

Across 65 payments — averaging $49.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Rxsight Inc$394
  • NEW World Medical,inc.$236
  • Johnson & Johnson Surgical Vision, Inc.$200
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$184
  • AbbVie$161
  • plus $442 from 9 others

What the payments were for

  • Travel & lodging$47015%
  • Food & beverage$2,72385%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,193 in reported general payments places this provider in the 70th percentile of 262 ophthalmology providers in Colorado.

See all ophthalmology providers in Colorado

Medicare billing

Part B allowed, 2024
$508,348
Medicare patients
613
Services billed
2,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj13$473,027
Prednisolone Acetate284$11,269
IlevroNepafenac18$6,802
Fluorometholone65$4,640
MoxifloxacinMoxifloxacin Hcl174$3,585
ValacyclovirValacyclovir Hcl44$1,770
Brimonidine Tartrate28$564
Ketorolac Tromethamine17$461
ErythromycinErythromycin Base23$307
Acetaminophen-CodeineAcetaminophen With Codeine15$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$95$473,02713 claims
NovartisIlevro$16$6,80218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 262 ophthalmology providers in Colorado.

Other ophthalmology in Loveland

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →